IMARC Group, a leading market research company, has released a report titled “Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global human insulin market size reached US$ 45.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 68.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.48% during 2023-2028.

Human insulin is a vital hormone produced by the pancreas in the human body. Its primary function is to regulate blood sugar levels, ensuring they remain within a narrow and healthy range. Insulin enables cells to absorb glucose from the bloodstream, where it can be used for energy or stored for later use. This hormone plays a pivotal role in maintaining overall health and well-being. Human insulin is of great significance in the medical field. Before the advent of recombinant DNA technology, insulin used for treating diabetes was extracted from the pancreases of animals, mainly pigs and cows. However, the introduction of synthetic human insulin in the early 1980s marked a significant breakthrough. This biosynthetic form of insulin is created through genetic engineering techniques, making it identical to the insulin produced by the human body.

For an in-depth analysis, you can refer sample copy of the report:

Human Insulin Market Trends and Drivers:

The foremost factor driving the global human insulin market is the escalating prevalence of diabetes worldwide. Both type 1 and type 2 diabetes require insulin therapy in various forms, thereby increasing the demand for human insulin. Additionally, the global demographic shift toward an aging population is contributing significantly to the growth of the market. As individuals age, the risk of developing diabetes increases, necessitating insulin treatment. Other than this, a higher healthcare expenditure per capita in many countries allows more individuals to access diabetes management and insulin therapy, fostering market growth. Besides this, pharmaceutical companies are investing heavily in research and development to create more effective and efficient insulin products. This innovation not only improves patient outcomes but also stimulates market growth. in line with this, sedentary lifestyles and unhealthy dietary habits contribute to the rising incidence of diabetes. As lifestyles continue to change, the demand for insulin products is expected to increase. Furthermore, rapid economic development in emerging markets is expanding the middle-class population, improving healthcare infrastructure, and increasing accessibility to insulin products, thereby boosting market growth. Moreover, the trend toward personalized medicine is gaining traction in diabetes treatment. Tailored insulin therapies based on individual patient profiles are becoming more common, driving demand for human insulin variants.

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • B. Braun Melsungen AG
  • Becton
  • Dickinson and Company (BD)
  • Biocon
  • Eli Lilly and Company
  • Gulf Pharmaceutical Industries (Julphar)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Groupe Sanofi
  • SEDICO Co.
  • Wockhardt Limited
  • Ypsomed AG

The report has segmented the market into the following categories:

Breakup by Product Type:

  • Drugs
    • Human Insulin Analogs and Biosimilars
      • Rapid Acting
      • Long Acting
      • Premixed
    • Human Insulin Biologics
      • Short Acting
      • Intermediate Acting
      • Premixed
  • Delivery Devices
    • Pens
      • Reusable Pens
      • Disposable Pens
    • Pen Needles
      • Standard Pen Needles
      • Safety Pen Needles
    • Syringes
    • Others

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

Breakup by Disease Type:

  • Type I Diabetes
  • Type II Diabetes

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Explore full report with table of contents:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US



USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal